| Old Articles: <Older 6981-6990 Newer> |
|---|
 |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.   |
The Motley Fool
December 21, 2010
Brian Orelli |
Our Drug Is Better Than Your Drug Without a question, Incyte's compound, INCB18424, works in myelofibrosis. Now that it has positive phase 3 results, it's time to get a brand name for the thing; INCB18424 just isn't that catchy. |
The Motley Fool
December 21, 2010
Brian D. Pacampara |
Martek Biosciences Shares Skyrocketed: What You Need to Know Martek Biosciences saw its shares soar a staggering 35% in early Tuesday trading after Dutch vitamin giant Royal DSM NV said it will bid $1.09 billion for the company. |
The Motley Fool
December 20, 2010
Brian Orelli |
A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto. |
The Motley Fool
December 20, 2010
Seth Jayson |
Should You Get Out of Medicis Pharmaceutical Before Next Quarter? The numbers don't paint a clear picture. For the last fully reported fiscal quarter, Medicis Pharmaceutical's year-over-year revenue grew 16.8%, and its AR grew 138.1%. That's a yellow flag. |
The Motley Fool
December 20, 2010
Seth Jayson |
Why the Street Should Love CareFusion's Earnings So how does the cash flow at CareFusion look? Take a peek at the chart below, which flags questionable cash flow sources with a red bar. |
The Motley Fool
December 17, 2010
Brian Orelli |
An Overnight Double: Santa Visits InterMune in Europe The Committee for Medicinal Products for Human Use issued a positive recommendation for the approval of InterMune's idiopathic pulmonary fibrosis treatment, Esbriet, sending shares up 140%. |
The Motley Fool
December 17, 2010
Rich Smith |
Upgrades and Downgrades and Updates (Oh My!) Goldman tweaks its estimates of Intuitive's prospects. |
The Motley Fool
December 17, 2010
Seth Jayson |
West Pharmaceutical Services Passes This Key Test For the last fully reported fiscal quarter, West Pharmaceutical Services' year-over-year revenue grew 4.8%. |
CIO
December 14, 2010
Kim S. Nash |
How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan. |
| <Older 6981-6990 Newer> Return to current articles. |
